Lixte Biotechnology (NASDAQ:NMAD – Get Free Report) released its quarterly earnings results on Monday. The company reported ($0.74) earnings per share for the quarter, FiscalAI reports. The firm had revenue of $0.47 million for the quarter.
Lixte Biotechnology Trading Down 13.9%
NMAD stock traded down $0.39 during trading on Tuesday, reaching $2.41. 240,106 shares of the stock were exchanged, compared to its average volume of 199,684. The firm has a market cap of $38.80 million, a P/E ratio of -2.41 and a beta of 1.37. Lixte Biotechnology has a twelve month low of $2.15 and a twelve month high of $8.38. The firm’s 50 day moving average is $3.73 and its 200 day moving average is $4.65.
Hedge Funds Weigh In On Lixte Biotechnology
Several large investors have recently bought and sold shares of the stock. Legacy Wealth Managment LLC ID purchased a new stake in Lixte Biotechnology in the 2nd quarter worth approximately $4,457,000. BlackRock Inc. purchased a new position in shares of Lixte Biotechnology in the 2nd quarter worth about $564,000. FNY Investment Advisers LLC bought a new position in Lixte Biotechnology during the second quarter valued at approximately $330,000. Finally, Equitable Holdings Inc. bought a new position in shares of Lixte Biotechnology during the 2nd quarter valued at $74,000. 5.10% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
Several equities research analysts recently weighed in on the stock. Wall Street Zen cut shares of Lixte Biotechnology from a “hold” rating to a “sell” rating in a research report on Saturday, August 22nd. Weiss Ratings upgraded Lixte Biotechnology from a “sell (e)” rating to a “sell (d)” rating in a research report on Friday, September 25th. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat.com, the stock presently has a consensus rating of “Sell”.
Read Our Latest Analysis on NMAD
About Lixte Biotechnology
Lixte Biotechnology Holdings is a clinical-stage biotechnology company focused on developing treatments for cancer. Its research centers on compounds that target protein phosphatase 2A (PP2A), an enzyme involved in cellular processes that can influence cancer growth and treatment response. The company’s lead investigational candidate, LB-100, is a small-molecule PP2A inhibitor being studied for potential use alongside existing cancer treatments. Lixte has described its approach as aiming to make tumors more responsive to therapies such as chemotherapy and immunotherapy.
See Also
- Five stocks we like better than Lixte Biotechnology
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
- Tyson Foods’ Earnings Beat Hides a Warning for Consumer Staples Dividend Investors
- 3 Stocks in an Overlooked Corner of Infrastructure With Hundreds of Billions at Stake
Receive News & Ratings for Lixte Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lixte Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
